nodes	percent_of_prediction	percent_of_DWPC	metapath
Mianserin—CYP1A2—Carmustine—lymphatic system cancer	0.0689	0.471	CbGbCtD
Mianserin—CYP3A4—Cytarabine—lymphatic system cancer	0.0246	0.168	CbGbCtD
Mianserin—CYP3A4—Teniposide—lymphatic system cancer	0.0243	0.166	CbGbCtD
Mianserin—Bone marrow depression—Teniposide—lymphatic system cancer	0.0233	0.0273	CcSEcCtD
Mianserin—Bone marrow depression—Fludarabine—lymphatic system cancer	0.0205	0.024	CcSEcCtD
Mianserin—CYP3A4—Mitoxantrone—lymphatic system cancer	0.017	0.116	CbGbCtD
Mianserin—Hepatic function abnormal—Teniposide—lymphatic system cancer	0.0131	0.0153	CcSEcCtD
Mianserin—Pancytopenia—Mechlorethamine—lymphatic system cancer	0.0127	0.0149	CcSEcCtD
Mianserin—Bone marrow depression—Vincristine—lymphatic system cancer	0.0125	0.0147	CcSEcCtD
Mianserin—Bone marrow depression—Mitoxantrone—lymphatic system cancer	0.0122	0.0143	CcSEcCtD
Mianserin—CYP3A4—Vincristine—lymphatic system cancer	0.0117	0.0798	CbGbCtD
Mianserin—Jaundice—Mechlorethamine—lymphatic system cancer	0.0116	0.0136	CcSEcCtD
Mianserin—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.0111	0.0131	CcSEcCtD
Mianserin—Cardiac failure—Fludarabine—lymphatic system cancer	0.0103	0.0121	CcSEcCtD
Mianserin—Tinnitus—Mechlorethamine—lymphatic system cancer	0.01	0.0117	CcSEcCtD
Mianserin—Pancytopenia—Teniposide—lymphatic system cancer	0.00938	0.011	CcSEcCtD
Mianserin—Neutropenia—Teniposide—lymphatic system cancer	0.00924	0.0108	CcSEcCtD
Mianserin—Hepatic enzyme increased—Mitoxantrone—lymphatic system cancer	0.0087	0.0102	CcSEcCtD
Mianserin—Vertigo—Mechlorethamine—lymphatic system cancer	0.00839	0.00983	CcSEcCtD
Mianserin—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00836	0.00979	CcSEcCtD
Mianserin—Pancytopenia—Fludarabine—lymphatic system cancer	0.00825	0.00966	CcSEcCtD
Mianserin—Neutropenia—Fludarabine—lymphatic system cancer	0.00812	0.00951	CcSEcCtD
Mianserin—Gynaecomastia—Carmustine—lymphatic system cancer	0.00792	0.00928	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00789	0.00925	CcSEcCtD
Mianserin—Arthritis—Bleomycin—lymphatic system cancer	0.00758	0.00888	CcSEcCtD
Mianserin—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00746	0.00874	CcSEcCtD
Mianserin—Skin disorder—Mechlorethamine—lymphatic system cancer	0.0074	0.00867	CcSEcCtD
Mianserin—Diplopia—Carmustine—lymphatic system cancer	0.00643	0.00753	CcSEcCtD
Mianserin—Anaemia—Teniposide—lymphatic system cancer	0.00636	0.00745	CcSEcCtD
Mianserin—Agitation—Teniposide—lymphatic system cancer	0.00633	0.00741	CcSEcCtD
Mianserin—Leukopenia—Teniposide—lymphatic system cancer	0.00616	0.00722	CcSEcCtD
Mianserin—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.00612	0.00718	CcSEcCtD
Mianserin—Bone marrow depression—Methotrexate—lymphatic system cancer	0.00608	0.00712	CcSEcCtD
Mianserin—Pancytopenia—Bleomycin—lymphatic system cancer	0.00605	0.00708	CcSEcCtD
Mianserin—Hypertension—Teniposide—lymphatic system cancer	0.00594	0.00696	CcSEcCtD
Mianserin—Cardiac arrest—Vincristine—lymphatic system cancer	0.00584	0.00684	CcSEcCtD
Mianserin—Confusional state—Teniposide—lymphatic system cancer	0.00566	0.00664	CcSEcCtD
Mianserin—Oedema—Teniposide—lymphatic system cancer	0.00562	0.00658	CcSEcCtD
Mianserin—Anaemia—Fludarabine—lymphatic system cancer	0.00559	0.00655	CcSEcCtD
Mianserin—Agitation—Fludarabine—lymphatic system cancer	0.00556	0.00651	CcSEcCtD
Mianserin—Thrombocytopenia—Teniposide—lymphatic system cancer	0.0055	0.00644	CcSEcCtD
Mianserin—Tachycardia—Teniposide—lymphatic system cancer	0.00548	0.00642	CcSEcCtD
Mianserin—Leukopenia—Fludarabine—lymphatic system cancer	0.00541	0.00634	CcSEcCtD
Mianserin—Pruritus—Mechlorethamine—lymphatic system cancer	0.00539	0.00632	CcSEcCtD
Mianserin—Pancytopenia—Carmustine—lymphatic system cancer	0.00528	0.00618	CcSEcCtD
Mianserin—Hypotension—Teniposide—lymphatic system cancer	0.00525	0.00615	CcSEcCtD
Mianserin—Convulsion—Fludarabine—lymphatic system cancer	0.00524	0.00614	CcSEcCtD
Mianserin—Neutropenia—Carmustine—lymphatic system cancer	0.0052	0.00609	CcSEcCtD
Mianserin—Arthralgia—Fludarabine—lymphatic system cancer	0.00515	0.00603	CcSEcCtD
Mianserin—Myalgia—Fludarabine—lymphatic system cancer	0.00515	0.00603	CcSEcCtD
Mianserin—Pancytopenia—Vincristine—lymphatic system cancer	0.00504	0.0059	CcSEcCtD
Mianserin—Confusional state—Fludarabine—lymphatic system cancer	0.00498	0.00583	CcSEcCtD
Mianserin—Neutropenia—Vincristine—lymphatic system cancer	0.00496	0.00581	CcSEcCtD
Mianserin—Oedema—Fludarabine—lymphatic system cancer	0.00494	0.00578	CcSEcCtD
Mianserin—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.00491	0.00575	CcSEcCtD
Mianserin—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00489	0.00572	CcSEcCtD
Mianserin—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00484	0.00567	CcSEcCtD
Mianserin—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00483	0.00566	CcSEcCtD
Mianserin—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00483	0.00566	CcSEcCtD
Mianserin—Rash—Mechlorethamine—lymphatic system cancer	0.0048	0.00563	CcSEcCtD
Mianserin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0048	0.00562	CcSEcCtD
Mianserin—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00476	0.00557	CcSEcCtD
Mianserin—Weight increased—Mitoxantrone—lymphatic system cancer	0.0047	0.00551	CcSEcCtD
Mianserin—Feeling abnormal—Teniposide—lymphatic system cancer	0.00463	0.00542	CcSEcCtD
Mianserin—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00461	0.0054	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.0045	0.00527	CcSEcCtD
Mianserin—Jaundice—Mitoxantrone—lymphatic system cancer	0.00449	0.00526	CcSEcCtD
Mianserin—Paraesthesia—Fludarabine—lymphatic system cancer	0.00443	0.00519	CcSEcCtD
Mianserin—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00437	0.00512	CcSEcCtD
Mianserin—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00434	0.00508	CcSEcCtD
Mianserin—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.0043	0.00504	CcSEcCtD
Mianserin—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00426	0.00499	CcSEcCtD
Mianserin—Fatigue—Fludarabine—lymphatic system cancer	0.00426	0.00499	CcSEcCtD
Mianserin—Constipation—Fludarabine—lymphatic system cancer	0.00422	0.00495	CcSEcCtD
Mianserin—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00421	0.00493	CcSEcCtD
Mianserin—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00417	0.00489	CcSEcCtD
Mianserin—Eye disorder—Carmustine—lymphatic system cancer	0.00416	0.00487	CcSEcCtD
Mianserin—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00413	0.00484	CcSEcCtD
Mianserin—Anaemia—Bleomycin—lymphatic system cancer	0.0041	0.0048	CcSEcCtD
Mianserin—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00407	0.00477	CcSEcCtD
Mianserin—Asthenia—Teniposide—lymphatic system cancer	0.00403	0.00472	CcSEcCtD
Mianserin—Pruritus—Teniposide—lymphatic system cancer	0.00397	0.00466	CcSEcCtD
Mianserin—Leukopenia—Bleomycin—lymphatic system cancer	0.00397	0.00465	CcSEcCtD
Mianserin—Cardiac disorder—Vincristine—lymphatic system cancer	0.00394	0.00462	CcSEcCtD
Mianserin—Mental disorder—Carmustine—lymphatic system cancer	0.0039	0.00457	CcSEcCtD
Mianserin—Angiopathy—Vincristine—lymphatic system cancer	0.00385	0.00451	CcSEcCtD
Mianserin—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00383	0.00448	CcSEcCtD
Mianserin—Myalgia—Bleomycin—lymphatic system cancer	0.00378	0.00442	CcSEcCtD
Mianserin—Mental disorder—Vincristine—lymphatic system cancer	0.00372	0.00436	CcSEcCtD
Mianserin—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00367	0.0043	CcSEcCtD
Mianserin—Confusional state—Bleomycin—lymphatic system cancer	0.00365	0.00428	CcSEcCtD
Mianserin—Tremor—Carmustine—lymphatic system cancer	0.00363	0.00425	CcSEcCtD
Mianserin—Oedema—Bleomycin—lymphatic system cancer	0.00362	0.00424	CcSEcCtD
Mianserin—Anaemia—Carmustine—lymphatic system cancer	0.00358	0.00419	CcSEcCtD
Mianserin—Agitation—Carmustine—lymphatic system cancer	0.00356	0.00417	CcSEcCtD
Mianserin—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00354	0.00415	CcSEcCtD
Mianserin—Asthenia—Fludarabine—lymphatic system cancer	0.00354	0.00415	CcSEcCtD
Mianserin—Rash—Teniposide—lymphatic system cancer	0.00354	0.00415	CcSEcCtD
Mianserin—Dermatitis—Teniposide—lymphatic system cancer	0.00354	0.00415	CcSEcCtD
Mianserin—Headache—Teniposide—lymphatic system cancer	0.00352	0.00412	CcSEcCtD
Mianserin—Pruritus—Fludarabine—lymphatic system cancer	0.00349	0.00409	CcSEcCtD
Mianserin—Leukopenia—Carmustine—lymphatic system cancer	0.00347	0.00406	CcSEcCtD
Mianserin—Anaemia—Vincristine—lymphatic system cancer	0.00342	0.004	CcSEcCtD
Mianserin—Agitation—Vincristine—lymphatic system cancer	0.0034	0.00398	CcSEcCtD
Mianserin—Hypotension—Bleomycin—lymphatic system cancer	0.00338	0.00396	CcSEcCtD
Mianserin—Convulsion—Carmustine—lymphatic system cancer	0.00335	0.00393	CcSEcCtD
Mianserin—Hypertension—Carmustine—lymphatic system cancer	0.00334	0.00392	CcSEcCtD
Mianserin—Anaemia—Mitoxantrone—lymphatic system cancer	0.00333	0.0039	CcSEcCtD
Mianserin—Vertigo—Vincristine—lymphatic system cancer	0.00332	0.00389	CcSEcCtD
Mianserin—Leukopenia—Vincristine—lymphatic system cancer	0.00331	0.00388	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.0033	0.00386	CcSEcCtD
Mianserin—Myalgia—Carmustine—lymphatic system cancer	0.0033	0.00386	CcSEcCtD
Mianserin—Paraesthesia—Bleomycin—lymphatic system cancer	0.00325	0.00381	CcSEcCtD
Mianserin—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00322	0.00377	CcSEcCtD
Mianserin—Convulsion—Vincristine—lymphatic system cancer	0.0032	0.00375	CcSEcCtD
Mianserin—Hypertension—Vincristine—lymphatic system cancer	0.00319	0.00374	CcSEcCtD
Mianserin—Confusional state—Carmustine—lymphatic system cancer	0.00319	0.00373	CcSEcCtD
Mianserin—Oedema—Carmustine—lymphatic system cancer	0.00316	0.0037	CcSEcCtD
Mianserin—Myalgia—Vincristine—lymphatic system cancer	0.00315	0.00369	CcSEcCtD
Mianserin—Convulsion—Mitoxantrone—lymphatic system cancer	0.00312	0.00365	CcSEcCtD
Mianserin—Rash—Fludarabine—lymphatic system cancer	0.00311	0.00365	CcSEcCtD
Mianserin—Dermatitis—Fludarabine—lymphatic system cancer	0.00311	0.00364	CcSEcCtD
Mianserin—Hypertension—Mitoxantrone—lymphatic system cancer	0.00311	0.00364	CcSEcCtD
Mianserin—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00309	0.00362	CcSEcCtD
Mianserin—Headache—Fludarabine—lymphatic system cancer	0.00309	0.00362	CcSEcCtD
Mianserin—Tachycardia—Carmustine—lymphatic system cancer	0.00308	0.00361	CcSEcCtD
Mianserin—Myalgia—Mitoxantrone—lymphatic system cancer	0.00306	0.00359	CcSEcCtD
Mianserin—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00306	0.00359	CcSEcCtD
Mianserin—Lethargy—Methotrexate—lymphatic system cancer	0.00304	0.00356	CcSEcCtD
Mianserin—Oedema—Vincristine—lymphatic system cancer	0.00302	0.00353	CcSEcCtD
Mianserin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00298	0.00349	CcSEcCtD
Mianserin—Confusional state—Mitoxantrone—lymphatic system cancer	0.00296	0.00347	CcSEcCtD
Mianserin—Nervous system disorder—Vincristine—lymphatic system cancer	0.00296	0.00347	CcSEcCtD
Mianserin—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00295	0.00346	CcSEcCtD
Mianserin—Hypotension—Carmustine—lymphatic system cancer	0.00295	0.00346	CcSEcCtD
Mianserin—Oedema—Mitoxantrone—lymphatic system cancer	0.00294	0.00344	CcSEcCtD
Mianserin—Shock—Mitoxantrone—lymphatic system cancer	0.00289	0.00339	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00288	0.00337	CcSEcCtD
Mianserin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00288	0.00337	CcSEcCtD
Mianserin—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00287	0.00336	CcSEcCtD
Mianserin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00285	0.00334	CcSEcCtD
Mianserin—Paraesthesia—Carmustine—lymphatic system cancer	0.00284	0.00332	CcSEcCtD
Mianserin—Hypotension—Vincristine—lymphatic system cancer	0.00282	0.0033	CcSEcCtD
Mianserin—Somnolence—Carmustine—lymphatic system cancer	0.00281	0.00329	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00275	0.00322	CcSEcCtD
Mianserin—Hypotension—Mitoxantrone—lymphatic system cancer	0.00274	0.00322	CcSEcCtD
Mianserin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00273	0.0032	CcSEcCtD
Mianserin—Paraesthesia—Vincristine—lymphatic system cancer	0.00271	0.00317	CcSEcCtD
Mianserin—Constipation—Carmustine—lymphatic system cancer	0.0027	0.00317	CcSEcCtD
Mianserin—Breast disorder—Methotrexate—lymphatic system cancer	0.00269	0.00315	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00268	0.00314	CcSEcCtD
Mianserin—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00264	0.00309	CcSEcCtD
Mianserin—Somnolence—Mitoxantrone—lymphatic system cancer	0.00261	0.00306	CcSEcCtD
Mianserin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.0026	0.00305	CcSEcCtD
Mianserin—Feeling abnormal—Carmustine—lymphatic system cancer	0.0026	0.00305	CcSEcCtD
Mianserin—Fatigue—Vincristine—lymphatic system cancer	0.0026	0.00305	CcSEcCtD
Mianserin—Asthenia—Bleomycin—lymphatic system cancer	0.0026	0.00304	CcSEcCtD
Mianserin—Constipation—Vincristine—lymphatic system cancer	0.00258	0.00302	CcSEcCtD
Mianserin—Pruritus—Bleomycin—lymphatic system cancer	0.00256	0.003	CcSEcCtD
Mianserin—Fatigue—Mitoxantrone—lymphatic system cancer	0.00253	0.00297	CcSEcCtD
Mianserin—Constipation—Mitoxantrone—lymphatic system cancer	0.00251	0.00294	CcSEcCtD
Mianserin—Pancytopenia—Methotrexate—lymphatic system cancer	0.00244	0.00286	CcSEcCtD
Mianserin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00242	0.00284	CcSEcCtD
Mianserin—Neutropenia—Methotrexate—lymphatic system cancer	0.00241	0.00282	CcSEcCtD
Mianserin—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00237	0.00278	CcSEcCtD
Mianserin—Drowsiness—Methotrexate—lymphatic system cancer	0.00229	0.00269	CcSEcCtD
Mianserin—Rash—Bleomycin—lymphatic system cancer	0.00228	0.00267	CcSEcCtD
Mianserin—Dermatitis—Bleomycin—lymphatic system cancer	0.00228	0.00267	CcSEcCtD
Mianserin—Asthenia—Carmustine—lymphatic system cancer	0.00227	0.00266	CcSEcCtD
Mianserin—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00217	0.00254	CcSEcCtD
Mianserin—Asthenia—Vincristine—lymphatic system cancer	0.00216	0.00254	CcSEcCtD
Mianserin—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00214	0.00251	CcSEcCtD
Mianserin—Asthenia—Mitoxantrone—lymphatic system cancer	0.00211	0.00247	CcSEcCtD
Mianserin—Dizziness—Carmustine—lymphatic system cancer	0.00209	0.00245	CcSEcCtD
Mianserin—Hepatitis—Methotrexate—lymphatic system cancer	0.00206	0.00241	CcSEcCtD
Mianserin—Dizziness—Vincristine—lymphatic system cancer	0.00199	0.00234	CcSEcCtD
Mianserin—Rash—Carmustine—lymphatic system cancer	0.00199	0.00233	CcSEcCtD
Mianserin—Dermatitis—Carmustine—lymphatic system cancer	0.00199	0.00233	CcSEcCtD
Mianserin—Headache—Carmustine—lymphatic system cancer	0.00198	0.00232	CcSEcCtD
Mianserin—Eye disorder—Methotrexate—lymphatic system cancer	0.00193	0.00226	CcSEcCtD
Mianserin—Tinnitus—Methotrexate—lymphatic system cancer	0.00192	0.00225	CcSEcCtD
Mianserin—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00191	0.00224	CcSEcCtD
Mianserin—Rash—Vincristine—lymphatic system cancer	0.0019	0.00223	CcSEcCtD
Mianserin—Dermatitis—Vincristine—lymphatic system cancer	0.0019	0.00223	CcSEcCtD
Mianserin—Headache—Vincristine—lymphatic system cancer	0.00189	0.00221	CcSEcCtD
Mianserin—Angiopathy—Methotrexate—lymphatic system cancer	0.00187	0.00219	CcSEcCtD
Mianserin—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00186	0.00218	CcSEcCtD
Mianserin—Rash—Mitoxantrone—lymphatic system cancer	0.00185	0.00217	CcSEcCtD
Mianserin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00185	0.00217	CcSEcCtD
Mianserin—Headache—Mitoxantrone—lymphatic system cancer	0.00184	0.00216	CcSEcCtD
Mianserin—Mental disorder—Methotrexate—lymphatic system cancer	0.0018	0.00211	CcSEcCtD
Mianserin—Anaemia—Methotrexate—lymphatic system cancer	0.00166	0.00194	CcSEcCtD
Mianserin—Vertigo—Methotrexate—lymphatic system cancer	0.00161	0.00189	CcSEcCtD
Mianserin—Leukopenia—Methotrexate—lymphatic system cancer	0.00161	0.00188	CcSEcCtD
Mianserin—Convulsion—Methotrexate—lymphatic system cancer	0.00155	0.00182	CcSEcCtD
Mianserin—Arthralgia—Methotrexate—lymphatic system cancer	0.00153	0.00179	CcSEcCtD
Mianserin—Myalgia—Methotrexate—lymphatic system cancer	0.00153	0.00179	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00152	0.00178	CcSEcCtD
Mianserin—Confusional state—Methotrexate—lymphatic system cancer	0.00148	0.00173	CcSEcCtD
Mianserin—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00144	0.00168	CcSEcCtD
Mianserin—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00143	0.00168	CcSEcCtD
Mianserin—Skin disorder—Methotrexate—lymphatic system cancer	0.00142	0.00167	CcSEcCtD
Mianserin—Hypotension—Methotrexate—lymphatic system cancer	0.00137	0.0016	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00133	0.00156	CcSEcCtD
Mianserin—Paraesthesia—Methotrexate—lymphatic system cancer	0.00131	0.00154	CcSEcCtD
Mianserin—Somnolence—Methotrexate—lymphatic system cancer	0.0013	0.00152	CcSEcCtD
Mianserin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00126	0.00148	CcSEcCtD
Mianserin—Fatigue—Methotrexate—lymphatic system cancer	0.00126	0.00148	CcSEcCtD
Mianserin—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00121	0.00141	CcSEcCtD
Mianserin—Asthenia—Methotrexate—lymphatic system cancer	0.00105	0.00123	CcSEcCtD
Mianserin—Pruritus—Methotrexate—lymphatic system cancer	0.00104	0.00121	CcSEcCtD
Mianserin—Dizziness—Methotrexate—lymphatic system cancer	0.000968	0.00113	CcSEcCtD
Mianserin—Rash—Methotrexate—lymphatic system cancer	0.000923	0.00108	CcSEcCtD
Mianserin—Dermatitis—Methotrexate—lymphatic system cancer	0.000922	0.00108	CcSEcCtD
Mianserin—Headache—Methotrexate—lymphatic system cancer	0.000917	0.00107	CcSEcCtD
